Citations

Clear

9383 citation(s) found for "Thomas, PS".

Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real‐World Setting
Bennedsen, Tine Litske , Simonsen, Mikkel Runason , Jensen, Paw , Josefsson, Pär, Khurana, Arushi , Clausen, Michael Roost , Dessau‐Arp, Andriette, Jørgensen, Jennifer Bøgh , Jørgensen, Judit , Larsen, Thomas Stauffer , Pedersen, Lars Møller , Jakobsen, Lasse Hjort , Joergensen, Judit Mészáros , Clausen, Michael Roost , Pedersen, Lars Møller , Jensen, Paw , Brown, Peter de Nully , Maurer, Matthew J. , El‐Galaly, Tarec Christoffer

Mayo Clinic

European Journal of Haematology | January 9, 2025 | Volume: 114 | Issue: 5 | Pages: 832-839

10.1111/ejh.14373 | PMID 39786332 Get It

ABSTRACTThe development of new first‐line treatments for patients with follicular lymphoma (FL) is becoming increasingly challenging due to already excellent survival outcomes. The present study investigated the outcomes of patients with FL who underwent contemporary first‐line therapies but would not have been eligible for inclusion in recent trials and explored how commonly used in/exclusion criteria impacted their survival outcomes. This study included adult patients diagnosed with FL in the period 2000–2018 registered in the Danish Lymphoma Registry. Through searches on ClinicalTrials.gov, four recent 1st line phase 3 randomized controlled trials with R‐Bendamustine, R‐CVP, and/or R‐CHOP as control or experimental arms were included. Inclusion and exclusion criteria for each trial were retrieved and categorized. Patients were then divided into trial‐eligible and ineligible groups according to blood test results correlated to organ function and ECOG performance score (PS). Survival outcomes were significantly worse among trial‐ineligible patients, with adjusted differences between trial‐eligible and ineligible patients of 12%–20% in five‐year overall survival (OS) overall. Inclusion criteria based on PS and renal function were the main drivers of OS differences. More inclusive trials will lead to faster recruitment and secure focus on developing medicines for the group of patients with the worst outcomes.
Sleep Biomarker‐Based Characterization of Neurodegenerative Disorder Phenotypical Risk
Levendowski, Daniel J. , Walsh, Christine M. , Cho, Yeilim, Lee‐Iannotti, Joyce , Cho, Yeilim, Tsuang, Debby W. , Berka, Chris , Boeve, Bradley F. , Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089805 Get It

AbstractBackgroundIn this pilot study, the diagnostic agreement for sleep biomarker‐based neurodegenerative disorder (NDD) risk probabilities was evaluated in patients with Alzheimer’s disease dementia (AD), Lewy body disease (LBD), mild cognitive impairment (MCI), and controls (CG) with a Mini‐Mental State Exam scores ≥28.MethodsSleep biomarkers recorded with the Sleep Profiler (Advanced Brain Monitoring, Inc.) were used as inputs to a 4‐class machine learning algorithm trained to assign NDD risk probabilities to AD=27, LBD=19, isolated REM sleep behavior disorder=15, and CG=58. Input variables included age, time‐REM, non‐REM hypertonia, autonomic‐activation index, spindle‐duration, atypical‐N3, time‐supine, sleep‐efficiency, relative‐theta, and theta/alpha. Distributions of NDD risk were then assigned to AD=37, LBD=19, MCI=71, and CG=106 records.Records with CG output probabilities ≥70% were labeled Probably‐Normal, and from 45‐70% Likely‐Normal with indications of a NDD added when the LBD, AD or prodromal synucleinopathy (pSYN) risks exceeded approximately 25%. Similar thresholds were used to assign Likely‐ or Probably‐ LBD, AD, pSYN, or Mixed based on the group probabilities. Likely‐Normal with indications consistent with the diagnosis trended toward agreement.ResultsThe proportions of each group with classifications consistent with the diagnosis or trended toward agreement were CG=86%, MCI=75%, LBD=79%, and AD=87%.In the CG group, NDD risk assignments were Probably‐Normal=68% and Likely‐Normal with NDD indications=18%, Likely‐NDD=10%, and Probable‐NDD=4%.The MCI group was assigned Probable‐NDD=38% (AD=26%, Mixed=10%, LBD/pSYN=2%), Likely‐NDD=17% (AD=7%, Mixed=6%, LBD=3%, pSYN=1%), Likely‐Normal with indications=20% (AD=9%, pSYN=7%, Mixed=4%) and Probably‐Normal=25%The LBD group’s assigned risks consistent with the diagnoses included Probable‐NDD=74% and Likely‐Normal with pSYN indications=6% but included inconsistencies from Probable‐AD=5%, Likely‐Normal with AD indications=5%, and Probably‐Normal=11%.AD group’s consistent risk classifications included Probable‐NDD=60%, Likely‐NDD=11%, Likely‐Normal with AD/Mixed indications=13% and countered by inconsistencies from Probable‐LBD/pSYN=8%, Likely‐Normal with pSYN indications=3%, and Probably‐Normal=5%.ConclusionsConsistencies between the diagnoses and assigned NDD risks agreements exceeded 75% in all four groups. Studies are underway to confirm the test‐retest reliability and/or evaluate NDD risk probabilities in other patient populations.Support: NIH grants R44AG050326, R44AG054256, RO1AG060477, R33AG064271, ULRR024150, R34AG056639.
Design and Validation of the ADNI MR Protocol
Borowski, Bret, Felmlee, John, Thomas, David L. , Gunter, Jeffrey L. , Tosun, Duygu , Weiner, Michael S. W., Arani, Arvin , Reid, Robert I. , Buckner, Randy L. , Jung, Youngkyoo , Barkhof, Frederik , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.085261 Get It

AbstractBackgroundPhase four of the Alzheimer’s Disease Neuroimaging Initiative (ADNI4) began in 2023. This time‐period corresponded to MRI vendors introducing product sequences with compressed sensing (CS), cross‐vendor adoption of arterial spin‐labelling (ASL) and multi‐band slice excitation, and hardware improvements (head‐coils, increased gradient amplitudes). These advances enabled the acquisition of new imaging measures and reduced scan times. The ADNI4 MRI protocol aims to maintain longitudinal consistency across two decades of data acquisition, while adopting new technologies. Here we describe the design and justification behind the ADNI4 protocol and list the target imaging biomarkers.MethodsThe ADNI4 MRI protocol includes 9 MRI sequences; i) T1‐weighted (T1w) MP‐RAGE, ii) a compressed sensing T1w MP‐RAGE, iii) 3D T2w FLAIR, iv) structural isotropic 3D T2w v) T2*‐weighted susceptibility imaging vi) multi‐post labelling delay (PLD) 3D ASL, vii) 2D multi‐band‐multiple‐shell diffusion (dMRI), viii) 2D multi‐band EPI BOLD ix) high resolution, limited field of view, imaging centered on the hippocampus. Table 1 gives a detailed summary of the key protocol parameters and lists some of the imaging biomarkers that can be obtained from each series.ResultsStructural imaging was kept consistent across imaging sites. Variations in vendor specific sequences, software upgrades, and hardware performance capabilities, resulted in variations in advanced imaging strategies. Table 2 highlights the advanced sequences introduced in ADNI4, which will gradually be implemented as the required upgrades and licenses are obtained at each site. The main advanced sequences that are new in ADNI4 from ADNI 3 are i) CS for T1w images, ii) pseudo‐continuous‐ASL (pCASL) being implemented on all 3 vendors (GE, Siemens, Philips), iii) multi‐PLD ASL, which allows for the generation of quantitative maps of cerebral blood‐flow (CBF) and arterial transit times (ATTs), iv) and isotropic 1mm3 resolution for 3D FLAIR. When ADNI4 began, product sequences that utilized artificial intelligence were not widely available and could not be adequately tested before the rollout of ADNI4.ConclusionsThe ADNI4 database will continue to help the neuroimaging community, not only extract valuable imaging biomarkers, but provide the data necessary to test the impact of advanced imaging strategies on diagnostic accuracy and disease sensitivity.
SomaScan plasma proteomics of cSVD
Chen, Jingsha, Yang, Yunju , Fornage, Myriam, Peng, Zhongsheng , Daya, Gulzar N. , Longstreth, W.T., Kalani, Rizwan , Sharma, Malveeka , Psaty, Bruce M., Mosley, Thomas H., Hughes, Timothy M. , Gómez, Gabriela , Shi, Liu , Fohner, Alison E. , Fornage, Myriam , Duggan, Michael R. , Tin, Adrienne , Schlosser, Pascal , Psaty, Bruce M , Nevado‐Holgado, Alejo J. , Buckley, Noel J. , Gottesman, Rebecca F. , Lutsey, Pamela L. , Jack, Clifford R. , Sullivan, Kevin , Mosley, Thomas H. , Coresh, Josef , Walker, Keenan A.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.084576 Get It

AbstractBackgroundCerebral small vessel disease (cSVD), as defined by neuroimaging characteristics such as white matter hyperintensities (WMHs), cerebral microhemorrhages (CMHs), and lacunar infarcts, is highly prevalent and has been associated with dementia risk and other clinical sequelae. Although risk factors for cSVD have been identified, little is known about the biological processes and molecular mediators that influence cSVD development and progression.MethodsWithin the Atherosclerosis Risk in Communities (ARIC) study, we used SomaScan Multiplexed Proteomic technology to relate 4,877 plasma proteins to concurrently measured MRI‐defined cSVD characteristics, including WMHs, CMHs, and lacunar infarcts, in late‐life (n=1508; mean age: 76). Candidate protein associations with WMH volume were replicated in the Cardiovascular Health Study (n=765; mean age: 73) and Baltimore Longitudinal Study of Aging (n=902; mean age: 66). Cohort‐specific effect estimates were pooled using a fixed‐effect, inverse variance weighted meta‐analysis. Within 4228 non‐demented older adults in ARIC, we examined the association of WMH‐associated proteins with eight‐year dementia risk (641 incident dementia cases) using multivariate Cox proportional hazard models. All multivariate regression models were adjusted for demographic, kidney function, and cardiovascular risk variables.ResultsThis proteome‐wide analysis of older adults identified 13 WMH‐associated plasma proteins involved in synaptic function, endothelial integrity, and angiogenesis (Figures 1a, 2a). Nine of these proteins replicated in one or more external cohort (Figures 1b, 2b) and two proteins, oligodendrocyte myelin glycoprotein (OMG) and neuronal pentraxin receptor (NPTXR), remained associated with late‐life WMH volume when measured nearly two decades earlier during midlife (Figures 1c, 2c). Eight of the 13 WMH‐associated proteins were associated with lacunar infarcts, 6 with subcortical CMHs, and 4 with lobar CMHs (Figures 1d, 2d). Although none of the genes coding for WMH‐associated proteins have been nominated by WMH GWAS, 7 of these genes have been previously linked to cardiometabolic traits known to influence cSVD, such as blood pressure and cholesterol (Figures 1e, 2e). Finally, 11 candidate proteins were associated with incident dementia, underscoring their clinical relevance (Figures 1f, 2f).ConclusionsThis large‐scale proteomic analysis within longitudinal community‐based samples identified several plasma proteins, including OMG and NPTXR, as top candidate biomarkers for elevated WMH volume and its clinical manifestations.
Proteomic Analysis Resolves Distinct Molecular Signatures in Alzheimer’s Disease Brain Across Diverse Racial Groups
Fox, Edward J., Liu, Yue , Modeste, Erica , Duong, Duc M. , Yin, Luming, Gearing, Marla , Reddy, Joseph S. , Allen, Mariet , Quicksall, Zachary , Scanlan, Jo, Linden, Abby Vander , Poehlman, William L. , Chen, Xianfeng , Baheti, Saurabh , Ho, Charlotte C.G. , Nguyen, Thuy , Yepez‐Sisalema, Geovanna, Mitchell, Adriana O., Oatman, Stephanie R., Carrasquillo, Minerva M. , Beach, Thomas G., Golde, Todd E. , Haroutunian, Vahram, Zhang, Bin , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Seyfried, Nicholas T. , Disease, Accelerating Medicine Partnership for Alzheimer’s (AMP‐AD) Diversity Initiative, Seifar, Fatemeh , Shantaraman, Anantharaman , Lah, James J. , Heath, Laura , Wang, Erming , Wang, Minghui , Wang, Xue , Carrasquillo, Minerva M. , Runnels, Alexi , Beach, Thomas G. , Barnes, Lisa L. , Haroutunian, Vahram , Soni, Rajesh K , Greenwood, Anna, Levey, Allan I. , Wingo, Aliza P. , Wingo, Thomas S , Disease, Accelerating Medicine Partnership for Alzheimer’s (AMP‐AD) Diversity Initiative

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.092542 Get It

AbstractBackgroundAlzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within the non‐Hispanic White (NHW) population. To address this, Accelerating Medicines Partnership in AD (AMP‐AD) aimed to promote inclusivity in multi‐omics AD research, to unravel unique molecular signatures and pathways. The study aimed to provide comprehensive insights into the proteomic landscape of AD across diverse racial groups.MethodDorsolateral prefrontal cortex (DLPFC) and superior temporal gyrus (STG) brain tissues were donated from multiple centers (Mayo Clinic, Emory University, Rush University, Mt. Sinai School of Medicine) and were harmonized through neuropathological evaluation, specifically adhering to the Braak staging and CERAD criteria. Among 1105 DLPFC tissue samples (980 unique individuals), 322 were from African American donors, 214 from Latino Americans, 551 from NHW donors, and the rest were from a mixed or unknown racial background. Among 280 STG samples, 86 were African American, 76 Latino American, 116 NHW and the rest were mixed or unknown ethnicity. All tissues were uniformly homogenized and analyzed by tandem mass tag‐based mass spectrometry (TMT‐MS). Following quality control (QC), proteins with more than 50% missing values were removed and iterative principal component analysis was conducted to remove outliers within brain regions. Differential protein expression was conducted within and across races after adjusting for batch using regression‐analysis.ResultIn total, 9,180 proteins from the DLPFC, and 9,734 proteins from STG brain tissues were quantified by TMT‐MS. Further analysis identified approximately 3,000 differentially abundant proteins in AD brains compared to controls within race. The AD‐associated differentially abundant proteins were strongly correlated between DLPFC and STG regions and with CERAD and Braak. Protein levels of MAPT and APP demonstrated equivalent disease‐related elevations in both African American and NHW individuals with AD. Notably, after adjusting for AD, significant differences in protein levels were identified across race.ConclusionThe proteomics approach employed by AMP‐AD sheds light on the brain proteome in AD across diverse racial groups, emphasizing the importance of inclusive research in establishing robust and generalizable discoveries. The identified proteins here could underscore racial disparities beyond disease association, contributing to a more nuanced understanding of AD pathophysiology.
Increase in white matter hyperintensities in long‐COVID depends on age and hospitalization during acute SARS‐CoV‐2
Atık, Merve, Kendall‐Thomas, June, Przybelski, Scott A. , Kantarci, Orhun H. , Toledano, Michel , Fought, Angela J. , Lesnick, Timothy G. , Gundry, Katie, Lorente, Alfredo, Thotland, Jeromy, Li, Xiufeng , Manousakis, Georgios , Metzler, Abby, Byrne, Keenan, Juttukonda, Meher R. , Salat, David H. , Sherman, Janet C. , Pollak, Lauren, Nabi, Mehreen, Rehman, Sana , Karmonik, Christof , Gillani, Syed A , Flores, Vanesa, Davis, Rachel, Ashizawa, Tetsuo , Ratai, Eva, Kantarci, Kejal, Harrold, G. Kyle , Zeydan, Burcu , Senjem, Matthew L. , Schwarz, Christopher G. , Silva, Ana Isabel , Joers, James M. , Lorente, Alfredo, Deelchand, Dinesh K. , Park, Young Woo , Lenglet, Christophe , Eberly, Lynn E. , Mukerji, Shibani S. , Yaşar, Sevil , Öz, Gülin , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.090998 Get It

AbstractBackgroundApproximately 10% of patients with acute SARS‐CoV‐2 infection present with persistent symptoms recognized as the long‐COVID. Neurological and cognitive symptoms are prevalent in long‐COVID, requiring a deeper understanding of the biological basis of this condition for potential therapeutic interventions. Cerebrovascular complications are observed during acute infection, underscoring the importance of understanding cerebrovascular outcomes. Our objective was to investigate white matter hyperintensities (WMH) as a potential indicator of microvascular disease associated with long‐COVID in the brainMethodParticipants with long‐COVID (n=71; hospitalized, n=9, non‐hospitalized, n=62 during the acute infection) and controls (n=50) who did not have a reported infection were recruited from the community at five US sites that participated in the COVID‐Brain‐Advanced‐Imaging‐Network (COVID‐BRAIN) project. To be included, participants with long‐COVID had to experience neurological or cognitive sequelae within 6 months after a confirmed infection and continued to show at least one neurological symptom. Clinical evaluation and MRI were performed an average of 20±10 months after the acute infection. WMH volumes were measured from the 3D T2‐weighted FLAIR MRIs using a semi‐automated approach for the WMH segmentation. A linear regression model predicting log transformed WMH volume was used to investigate the association of age, groups (hospitalized long‐COVID, non‐hospitalized long‐COVID, controls), and the interaction of these two predictors along with an adjustment for total intracranial volume. Additionally, predicted regression lines have been plotted on the untransformed WMH scale.ResultWe observed a greater age‐dependent increase in WMH volumes in the hospitalized patients with long‐COVID compared to the control group (group*age interaction, p=0.005). We did not observe this difference in slopes in the non‐hospitalized patients with long‐COVID compared to the controls. Figure shows the slopes of WMH volume as a percentage of the total intracranial volume by age in the three groups.ConclusionOur preliminary observation in this ongoing long‐Covid study suggests that hospitalization during acute COVID is associated with the age‐dependent increase in microvascular injury in the white matter. Older adults with acute infection that require hospitalization are more susceptible to cerebrovascular adverse outcomes than controls or those who do not require hospitalization. Impact of such microvascular changes on cognitive outcomes and persistence of post‐COVID symptoms is yet to be studied.
Association between gene expression and neurodegeneration in dementia with Lewy bodies
Baumann, Janna M., Przybelski, Scott A. , Calizzano, Francesco , Oppedal, Ketil , Kramberger, Milica G. , Habich, Annegret , Schwarz, Christopher G. , Pardini, Matteo , Inguanzo, Anna , Blanc, Frédéric , Lemstra, Afina W. , Hort, Jakub , Brendel, Matthias , Ochoa-Figueroa, M.A. , Garibotto, Valentina , Pilotto, Andrea , Boeve, Bradley F. , Aarsland, Dag , Westman, Eric , Dierks, Thomas , Kantarci, Kejal , Morbelli, Silvia , Jonkman, Laura E. , Ferreira, Daniel

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.086838 Get It

AbstractBackgroundPatterns of regional atrophy and hypometabolism have been observed in dementia with Lewy bodies (DLB). However, determinants of regional vulnerability to structural and functional neurodegeneration remain largely unexplored. First, we investigated the association between regional gene expression and grey matter volumes in probable DLB patients. Since hypometabolism presumably precedes overt brain atrophy, we additionally investigate the association between regional gene expression and hypometabolism in DLB.MethodTo investigate the association between gene expression and regional volumes, 165 DLB patients along with 165 age‐ and sex‐matched healthy controls from three European centres and the Mayo Clinic (USA) were included. Regional volumes were quantified from MRI using SPM12 in 112 cortical, subcortical, and cerebellar brain regions, and compared between groups, using w‐scores. Regional expression data of seven genes involved in the formation and degradation of pathological protein aggregates (APOE, APP, BIN1, GBA, MAPT, SNCA, TMEM175) was extracted from six healthy donors from the Allen Human Brain Atlas and correlated with regional volumetric w‐scores. To assess the predictive value of regional gene expression on regional volumes we used Gaussian stepwise backwards linear regression including all seven genes as predictors. To investigate the association between gene expression and hypometabolism, we are currently applying the same analysis pipeline to FDG‐PET data of 139 DLB patients from 8 European centres.ResultMost brain regions showed lower volumes in DLB patients compared to healthy controls, with differences being most pronounced in occipital and parietal lobes. Regional expression of APOE correlated positively with regional volumes in DLB. Conversely, regional expression of MAPT correlated negatively with regional volumes. Both APOE and MAPT gene expression were significant predictors of regional volumes in the regression analysis. None of the other gene expression values was significantly associated with regional volumes in DLB.ConclusionOur findings show that regional expression of genes associated with the abnormal accumulation of amyloid and tau, common co‐pathologies in DLB, partially account for the brain atrophy pattern observed in DLB patients. Analyses are ongoing for the hypometabolism pattern. Our finding emphasises the relevance of co‐pathologies in predicting atrophy progression and identifying potential targets for future disease‐modifying treatments.
Mid‐ to late‐life changes in blood‐based biomarkers of Alzheimer’s disease pathology and neurodegeneration and associations with brain amyloid deposition: The ARIC‐PET Study
Chen, Jinyu , Griswold, Michael , Wong, Dean F. , Sharrett, A. Richey , Mosley, Thomas H. , Gottesman, Rebecca F., Palta, Priya , Pike, James Russell , Lü, Yifei , Walker, Keenan A. , Sullivan, Kevin , Thyagarajan, Bharat , Mielke, Michelle M. , Lutsey, Pamela L. , Knopman, David S. , Coresh, Josef

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.091307 Get It

AbstractBackgroundBlood‐based biomarkers show promise as a noninvasive, inexpensive method for measuring Alzheimer’s disease pathology throughout the lifecourse. However, the predictive and classification accuracy of these biomarkers at different stages of the lifecourse and among diverse, community‐dwelling populations requires further investigation.MethodBetween 2014 and 2015, 329 dementia‐free participants from the Atherosclerosis Risk in Communities Study underwent brain magnetic resonance imaging (MRI) and florbetapir positron emission tomography (PET). Amyloid positivity was defined as a global cortex standardized uptake value ratio greater than 1.2. Stored plasma samples collected in midlife (1993‐95, mean age 58.5 years) and late‐life (2011‐13, mean age 76.2 years) from a subsample of 259 participants were assayed in 2022 using Quanterix SiMoA. The assay quantified amyloid‐β (Aβ)42/40, phosphorylated tau at threonine 181 (p‐Tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP). Unadjusted and covariate‐adjusted logistic regression models estimated the association between plasma biomarkers from midlife and late‐life and amyloid positivity in late‐life. Unadjusted receiver operating characteristic curves documented the classification accuracy of the plasma biomarkers separately and collectively.ResultThe sample (Table 1) included 151 women (58.1%), 105 Black participants (40.4%), and 136 (52.3%) participants with amyloid positivity. In models adjusted for demographics, lifestyle factors, cardiovascular factors, and the presence of APOE ε4 alleles, assays measured in midlife were not associated with amyloid positivity in late‐life (Table 2). However, late‐life measurements of Aβ42/40, p‐Tau181, and GFAP and change per decade from midlife to late‐life in p‐Tau181 and GFAP were associated with greater odds of amyloid positivity. The greatest classification accuracy (Figure 1) was achieved by using all assays measured in midlife and late‐life (AUC = 0.754), although the accuracy when using only late‐life measures was comparable (AUC = 0.737).ConclusionLate‐life plasma biomarkers of Alzheimer's disease neuropathology and astrogliosis were associated with late‐life amyloid positivity, but midlife plasma biomarkers obtained 16 to 20 years earlier did not exhibit a statistically significant association. Additional longitudinal research is needed to determine whether changes in plasma biomarkers measured before an individual is classified as amyloid positive can be used to identify individuals at risk of developing Alzheimer's disease.
Associations of Alzheimer’s and Neurodegeneration Blood Biomarkers with Prevalent and Incident Mobility and Cognitive Impairment
Windham, B. Gwen , Blackshear, Chad , Ali, Farwa , Mosley, Thomas H. , Palta, Priya , Griswold, Michael , Knopman, David S. , Walker, Keenan A. , Pike, James Russell , Lü, Yifei

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.086174 Get It

AbstractBackgroundOlder adults with dual cognitive and mobility impairments have higher financial costs and poorer quality of life than adults with either impairment alone. Blood biomarkers of Alzheimer Disease (AD) pathology (Aβ42, Aβ40 and p‐tau181) and neurodegeneration (neurofilament light (NFL) and glial fibrillary acidic protein (GFAP)) may identify individuals at risk for both mobility and cognitive impairment and provide novel insights into mechanistic underpinnings.MethodBlood biomarkers (SiMoA Quanterix N4PE, p‐tau181 single‐plex) were available in a subsample of 1751 ARIC study participants at Visit 5 (V5, 2011‐13, mean age 76.2 years (5.3), 41% men, 28% Black); Aβ42 was reversed and adjusted for Aβ40 (‐Aβ42|40) for consistent directions of associations (higher=worse). Usual gait speed and cognitive status were assessed over 8 years at V5, V6 (2016‐17), and V7 (2017‐18). Participants were categorized by V5 impairment: mobility‐only (gait speed <0.8m/s, n=430), cognitive‐only (expert‐adjudicated dementia, n=38), dual (n=54), or neither (referent, n=1229). Multinomial regression models examined relative risk ratios (RRR) of V5 log‐transformed biomarkers with prevalent impairments and, among those with neither impairment at V5, incident impairments through V7. All models adjusted for V5 age, sex, self‐reported race (Black or White), renal function, and body mass index.ResultHigher levels of all biomarkers were associated with greater risk of prevalent impairment in mobility, cognitive, or dual domains (Figure A). Over 8‐years of follow‐up, incident impairments included 471 participants with only mobility impairments, 39 with only cognitive impairments, 55 with dual impairments, and 168 died without developing any impairment. All biomarkers were associated with incident dual impairment per IQR higher biomarker: p‐tau181 (RRR=2.54; 95% CI: 1.45, 4.44), ‐Aβ42|40 (RRR=1.66; 1.31, 2.09), NfL (RRR=2.69; 1.22, 5.91) and GFAP (RRR=2.13; 1.07, 4.25). P‐tau181, ‐Aβ42|40, and GFAP were also associated with incident cognitive‐only impairment, while P‐tau181, NFL and GFAP were associated with incident mobility‐only impairment. (Figure B).ConclusionBlood biomarkers of brain health may be useful tools for earlier identification of those at risk for cognitive, mobility, or dual declines, facilitating earlier targeted interventions. Potential differences in AD‐pathology versus neurodegeneration blood biomarker relationships with outcomes of mobility and cognition may help to identify more targeted interventions for both.
A Modified Mediterranean Ketogenic Diet reverses signatures and mitigates modifiable risk factors of Alzheimer’s disease
Schweickart, Annalise , Huynh, Kevin, Wang, Tingting , Mellett, Natalie A. , Shi, Pixu , Zemlin, Jasmine , Rahman, Gibraan , Panitchpakdi, Morgan , Meehan, Michael J. , Schimmel, Leyla , Blennow, Kaj, Blach, Colette , Dorrestein, Pieter C. , Krumsiek, Jan , Craft, Suzanne , Huynh, Kevin , Batra, Richa , Neth, Bryan J. , Martino, Cameron , Dilmore, Amanda Hazel , Giles, Corey , Duong, Thy , Shenhav, Liat , Zhang, Anru R. , Karu, Naama , West, Kiana , Weldon, Kelly C. , Register, Thomas C. , Arnold, Matthias , Meikle, Peter J. , Blennow, Kaj , Zetterberg, Henrik , Knight, Rob , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S7 | Pages: No page available

10.1002/alz.089878 Get It

AbstractBackgroundAlzheimer’s disease (AD) is a neurodegenerative disorder with significant environmental factors, including diet, that influence its onset and progression. While the ketogenic diet (KD) holds promise in reducing metabolic risks and potentially affecting AD progression, only a few studies have explored the KD’s molecular impact for markers of AD therapeutic potential. The BEAM diet study simultaneously profiled the KD’s effect on the lipidome, blood and cerebrospinal metabolome, and microbiome of both cognitively impaired and cognitively normal individuals. The findings summarized here assess the biological impact of a Modified Mediterranean KD in the context of Alzheimer’s disease treatment and prevention.MethodBEAM involved participants at risk for AD, either cognitively normal or with mild cognitive impairment. The participants consumed both a modified Mediterranean‐ketogenic diet (MMKD) and the American Heart Association diet (AHAD) for 6 weeks each, separated by a 6‐week washout period. We employed HPLC‐MS/MS lipidomics profiling in plasma, nuclear magnetic resonance (NMR)‐based metabolomics to profile serum and CSF, and metagenomics profiling on fecal samples before and after each diet to assess dietary‐induced changes.ResultThe MMKD led to significant alterations in the blood, CSF, and microbiome. These changes included a global elevation across all plasmanyl and plasmenyl ether lipid species, improved modifiable risk factors, like increased HDL‐C and reduced BMI, the reversal of serum metabolic disturbances linked to AD such as an increase in valine levels, and a reduction in systemic inflammation. Leveraging prior clinical studies on AD (n = 1,912), we found that MMKD was inversely associated with the peripheral lipidomic signature of prevalent and incident AD. In the CSF, the MMKD was linked to modified amino acid levels and the breakdown of branched‐chain amino acids (BCAAs). Importantly, we observed a strong correlation between metabolic changes in the CSF and serum, suggesting a systemic regulation of metabolism. In addition, participants with MCI on the MMKD had lower levels of GABA‐producing microbes and GABA, and higher levels of GABA‐regulating microbes.ConclusionOur findings highlight that MMKD can improve AD‐related risk factors, reverse some metabolic disturbances associated with AD, and align metabolic changes across the blood‐CSF barrier.Funding: Alzheimer’s Gut Microbiome Project, NIA U19AG063744